Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cendakimab DDI Study in Eosinophilic Esophagitis
NCT05175352Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cendakimab in eosinophilic esophagitis (EoE), sponsored by Celgene Corporation. Primary endpoints: Area under the concentration-time curve from time zero to infinity up to 18 Weeks and Area under the concentration-time curve from time zero to 12 hours postdose. Started Jun 2022; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05175352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175352.